Helus Pharma
Update in progressHELP (NasdaqGM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Cybin Inc., doing business as Helus Pharma, is a clinical-stage neuropsychiatry company developing psychedelic-based therapeutics. Its programs include CYB003, a deuterated psilocybin analog in phase 3 for major depressive disorder; CYB004, a deuterated DMT in phase 2 for generalized anxiety disorder; SPL028 (deuterated DMT) completed phase 1; SPL026 for MDD; and CYB005, a preclinical phenethylamine derivative. Headquartered in Toronto, it also has a Segal Trials partnership for the PARADIGM program.
Company score
- Sentiment
- 0.34
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.21
- Governance
- 0.09
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.08
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.21
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGM (NGM)
- LocationCanada
- CEOMr. Eric So L.L.B.
- Employees100
- Websitewww.helus.com
Identifiers
- ISINCA23256X4075
- FIGIBBG00MFNRRT4